Last update 01 Nov 2024

Aanastra Inc.

Private Company|
United States
|

Overview

Basic Info

Introduction
AANASTRA (formerly AADIGEN) specializes in the development of in vivo targeted RNA therapeutics in the treatment of cancers and genetic diseases. The company’s technology is based on proprietary RNA and proprietary peptides complexed together for targeted in vivo delivery of RNA. Our versatile breakthrough technology tackles the major stumbling block in RNA therapeutics which continues to be the systemic in vivo targeting and cellular-release of RNA-based agents. Our approach provides an effective strategy for a wide range of clinical applications and pathologies. The company was founded by Dr. Neil Desai (Abraxis, Celgene, Aadi Bioscience) and the technology and its use in the delivery of RNA therapeutics is based on the original research of Dr. Gilles Divita, who pioneered the cell penetrating peptide strategy for oligonucleotide delivery. Aanastra (Los Angeles, CA) works closely on its RNA therapeutics technology with its sister company Divincell SAS (Nimes, France).

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Respiratory Diseases
mRNA
CRISPR/Cas
mRNA vaccine

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
mRNA9
CRISPR/Cas4
mRNA vaccine1

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
14
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ADGN-531
( KRAS G12C x PARP x p53 )
Neoplasms
More
Preclinical
ADGN-CRP-104
Pulmonary Fibrosis
More
Preclinical
ADGN-902
( BRCA1 )
Breast Cancer
More
Preclinical
PCSK9 GENE EDITING
( PCSK9 )
Hypercholesterolemia
More
Preclinical
ADGN-CRP-102
Liver Diseases
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free